Jun 22, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 27, 2020
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
May 15, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
May 07, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
Apr 30, 2020
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
Apr 13, 2020
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
Mar 31, 2020
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
Feb 27, 2020
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
Feb 10, 2020
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
Dec 19, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
Oct 30, 2019
ESSA Pharma Grants Stock Options
Oct 28, 2019
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 07, 2019
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
Sep 28, 2019
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
Sep 19, 2019
ESSA to Present at Ladenburg Thalmann Healthcare Conference
Sep 05, 2019
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Aug 27, 2019
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
Aug 23, 2019
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
Aug 14, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
Jul 31, 2019
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective